Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Lorlatinib by Pfizer for Neuroblastoma: Likelihood of Approval
Lorlatinib is under clinical development by Pfizer and currently in Phase I for Neuroblastoma. According to GlobalData, Phase I drugs...